About Excelra
Excelra is a company based in Hyderabad (India) founded in 2001. Excelra has raised $163.84 thousand across 1 funding round from investors including Destiny Investments. The company has 622 employees. Excelra has completed 1 acquisition, including BISC Global. Excelra offers products and services including GOSTAR™ Small Molecules, BioVisualizer™, and Online Pipeline Platform (OP²)®. Excelra operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Hyderabad, India
- Employees 622
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website excelra.com
- Social LinkedIn X Facebook Instagram
- Legal Name Excelra Knowledge Solutions Private Limited
- Date of Incorporation 24 Feb, 2006
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹306 Cr
FY 2025 · -1% YoY
- Net Profit₹1.93 Cr
FY 2025 · 1% margin
- EBITDA₹44.73 Cr
FY 2025 · 15% margin
- Total Equity Funding$163.84K (USD)
in 1 rounds
- Latest Funding Round$163.84K (USD), Seed
Jul 2016
- Investors
- Employee Count622
- Investments & Acquisitions
Associated legal entities of Excelra
Excelra operates through Excelra Knowledge Solutions Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Excelra Knowledge Solutions Private Limited CIN U72100TG2006PTC049287 | Active | 24 Feb 2006 | Hyderabad, Telangana | ₹306 Cr | 622 | 6 | View details |
Products & Services of Excelra
Excelra offers a comprehensive portfolio of products and services, including GOSTAR™ Small Molecules, BioVisualizer™, and Online Pipeline Platform (OP²)®.
SAR database for small molecule drug discovery and analysis
Platform for visualizing and analyzing biomedical data
No-code tool for sequencing data processing and insights
Funding Insights of Excelra
Excelra has successfully raised a total of $163.84K through 1 strategic funding round. The most recent funding activity was a Seed round of $163.84 thousand completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $163,836
- Total Rounds 1
- Last Round Seed — $163,836
- First Round $163,836
(Jul 2016)
- Investors Count 1
All 1 funding rounds of Excelra with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2016 | $163,836 | Seed | – | Destiny Investments | – |
1 investors in total: 1 institutional.
Investors in Excelra
Excelra has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Destiny Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provides comprehensive investment advisory services to help clients achieve financial goals. | 2006 | destinyinvestmentsllc.com | Metairie, United States |
Investor details for Excelra
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Excelra Knowledge Solutions Private Limited (Excelra)
Excelra Knowledge Solutions Private Limited is the primary company behind Excelra. The board of Excelra Knowledge Solutions Private Limited currently have 5 directors; the longest-serving is Venkata Sanjayreddy Gunupati, appointed in 2006. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Venkata Sanjayreddy Gunupati DIN 00005282 | Director | 24 Feb 2006 | 20 yrs 7 mo | Excelra Knowledge Solutions Private Limited |
| Davinder Singh Brar DIN 00068502 | Director | 24 Feb 2006 | 20 yrs 7 mo | Excelra Knowledge Solutions Private Limited |
| Anandbir Singh Brar DIN 07155420 | Director | 16 Jun 2022 | 4 yrs 3 mo | Excelra Knowledge Solutions Private Limited |
| Sudip Nandy DIN 07199187 | Director | 16 Jun 2022 | 4 yrs 3 mo | Excelra Knowledge Solutions Private Limited |
| Sidharth Indukuri Reddy DIN 03240068 | Director | 16 Jun 2022 | 4 yrs 3 mo | Excelra Knowledge Solutions Private Limited |
People of Excelra
39 people are tracked at Excelra (19 in leadership, 20 in team); the tracked headcount is 622.
| Name | Role | Group |
|---|---|---|
| – | Leadership | |
| CEO | Leadership | |
Nicolas Goffard | Director, Key Account Management Europe | Leadership |
Norman Azoulay | Vice President, Platforms And Data | Leadership |
Laasyaa P. Chadaga | VP, Finance & Legal | Leadership |
Sujatha Mudumala | Global Head - Finance & Legal | Leadership |
Jitendra Parekh | Vice President - Scientific Informatics (r&d Technology) | Leadership |
Mahendra Pratap Singh | Vice President - HR | Leadership |
Lokesh Bhagchand | Chief Operating Officer | Leadership |
Vikash Peesapati | Director - Corporate Development And Strategy | Leadership |
Amar Thyagarajan | Chief Commercial Officer (cco) | Leadership |
Bindu Ajithkumar | Director Global Marketing | Leadership |
Chakshu Kalra | Deputy General Manager- Talent Management, Learning And Od. HRBP Engagement & Recognition | Leadership |
Sanjeev Rao Yelubandi | General Manager, Legal & Company Secretary | Leadership |
Mukesh Navgire | Deputy General Manager | Leadership |
Stephani Lane | Sr. US HR Business Partner | Leadership |
Anil Kumar M. | Associate Director | Leadership |
Maniram Reddy Etakala | Associate Director-corporate Services & Procurement | Leadership |
Naveen Kumar | Dy General Manager | Leadership |
Pratik Dube | Talent Acquisition Manager | Team |
19 more people are available in the full profile.
Complete people profiles for Excelra
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Excelra
Figures of Excelra Knowledge Solutions Private Limited, the primary company behind Excelra, for FY 2025. Revenue was ₹306 Cr (-1% year on year). Net profit was ₹1.93 Cr (1% margin). EBITDA was ₹44.73 Cr (15% margin). Revenue has grown at a compounded annual rate of +10% over three years and +301% over five years.
- ₹306 CrRevenue · FY 2025 · -1% YoY
- ₹1.93 CrNet profit · 1% margin
- ₹44.73 CrEBITDA · 15% margin
- ₹56.66 CrPaid-up capital
- 622Employees (provident fund records)
- +10%Revenue CAGR, 3 years
- +301%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Excelra Knowledge Solutions Private Limited are on its company page.
Detailed financial statements for Excelra
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Excelra
Excelra has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include BISC Global.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Bioinformatics and biostatistics services are provided to life science firms. | biscglobal.com | Ghent, Belgium | 2017 | Apr 2023 | •••• |
Complete acquisition details for Excelra
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Excelra
3 dated milestones of Excelra across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Excelra is founded.
- Funding First funding round of $164K.
- Acquisition Acquires BISC Global.
Competitors of Excelra
Excelra operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Excelra
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Excelra
The website of Excelra (excelra.com) receives about 14.7K visits a month and ranks #2,534,346 among all websites worldwide, #3,480 in Biotechnology and Pharmaceuticals.
- Monthly visits14.7K
▲ 73.3% vs previous month
- Unique visitors3.4K
per month
- Global rank#2,534,346
among all websites
- Category rank#3,480
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.8
- Average visit27 sec
- DevicesDesktop 33% · Mobile 67%
Latest news on Excelra
Complete news archive for Excelra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Excelra
10 companies that operate in the same segment as Excelra (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Excelra
Excelra was founded in 2001 and raised its 1st funding round 15 years after it was founded.
Excelra is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Anandbir Singh Brar is the current CEO of Excelra.
Excelra is a funded company, having raised a total of $163.84K across 1 funding round to date. The company's 1st funding round was a Seed of $163.84K, raised on Jul 2016.
Excelra has 622 employees.
The primary company behind Excelra, Excelra Knowledge Solutions Private Limited, reported revenue of ₹306 Cr for FY 2025, down 1% year on year.
Excelra develops a bioinformatics platform for the in silico analysis of drug candidate. The companys product GOSTAR is a SAR database that provides information on SAR, ADME, toxicity, preclinical, clinical, and structural data, GOBIOM is a repository of biomarkers reported in pre-clinical, clinical and exploratory phases, CTOD is a Clinical Trial Outcome Database. The company also develops and markets a suite of clinical trial outcomes databases. It also develops clinical databases that support MBMA on a custom basis. It also offers services for drug and biomarker discovery. It was previously known as GVK Informatics.
Excelra's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Excelra offers GOSTAR™ Small Molecules, BioVisualizer™, and Online Pipeline Platform (OP²)®.
Excelra has made 1 acquisition, including BISC Global.
Excelra has 1 investor. Key investors include Destiny Investments.
Excelra operates through Excelra Knowledge Solutions Private Limited.